Two recent findings from the European Medicines Agency now allow HAS to expand its COVID-19 vaccination strategy and, as a result, expand the number of drugs with the introduction of a fifth vaccine, Nuvaxovid.
It was developed according to the classical technology (adjuvant protein vaccine) and can be used as a means of primary vaccination.
It is clarified that this drug can also be used as a second dose for those who received the first shot with one of the other four approved drugs. At the same time, the regulator does not recommend the use of Nuvaxovid for revaccination, since there is still little data on the use of this drug and there is no necessary approval from the EMA.
In addition, the committee approved the use of Janssen’s drug for revaccination of the population.
Primary vaccination with its use now requires the introduction of two doses, and not one, as before.
– .
